title: Anti-tumour strategies aiming to target tumour-associated macrophages.
abstract: Tumour-associated macrophages (TAMs) represent a predominant population of inflammatory cells that present in solid tumours. TAMs are mostly characterized as alternatively activated M2-like macrophages and are known to orchestrate nearly all stages of tumour progression. Experimental investigations indicate that TAMs contribute to drug-resistance and radio-protective effects, and clinical evidence shows that an elevated number of TAMs and their M2 profile are correlated with therapy failure and poor prognosis in cancer patients. Recently, many studies on TAM-targeted strategies have made significant progress and some pilot works have achieved encouraging results. Among these, connections between some anti-tumour drugs and their influence on TAMs have been suggested. In this review, we will summarize recent advances in TAM-targeted strategies for tumour therapy. Based on the proposed mechanisms, those strategies are grouped into four categories: (i) inhibiting macrophage recruitment; (ii) suppressing TAM survival; (iii) enhancing M1-like tumoricidal activity of TAMs; (iv) blocking M2-like tumour-promoting activity of TAMs. It is desired that further attention be drawn to this research field and more effort be made to promote TAM-targeted tumour therapy.
authors.affiliation: Department of Geriatrics, State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Xiaoqiang
authors.initials: X
authors.lastname: Tang
authors.forename: Chunfen
authors.initials: C
authors.lastname: Mo
authors.forename: Yongsheng
authors.initials: Y
authors.lastname: Wang
authors.forename: Dandan
authors.initials: D
authors.lastname: Wei
authors.forename: Hengyi
authors.initials: H
authors.lastname: Xiao
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000276:immunology; D019008:Drug Resistance, Neoplasm / Q000276:immunology; D006801:Humans; D008264:Macrophages / Q000276:immunology* / Q000473:pathology; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D011836:Radiation Tolerance / Q000276:immunology